ストックスクリーナーアプリを入手
0.3654
4.37%
0.0153
アフターアワーズ：
.37
0.0046
+1.26%
前日終値:
$0.3501
開ける：
$0.38
24時間の取引高:
86,613
Relative Volume:
0.58
時価総額：
$22.96M
収益：
$37.20M
当期純損益:
$-11.85M
株価収益率:
-1.9151
EPS:
-0.1908
ネットキャッシュフロー:
$-10.59M
1週間 パフォーマンス:
+1.50%
1か月 パフォーマンス:
-2.30%
6か月 パフォーマンス:
-42.00%
1年 パフォーマンス:
-57.01%
1日の値動き範囲:
$0.3523
$0.385
1週間の範囲:
$0.35
$0.385
52週間の値動き範囲:
$0.35
$1.22
Cytosorbents Corp Stock (CTSO) Company Profile
Compare CTSO vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.3654 | 22.62M | 37.20M | -11.85M | -10.59M | -0.1908 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-09-07 | 開始されました | B. Riley Securities | Buy |
| 2021-10-14 | 再開されました | B. Riley Securities | Buy |
| 2020-09-17 | 開始されました | Jefferies | Buy |
| 2020-09-01 | 開始されました | SVB Leerink | Outperform |
| 2017-08-08 | 繰り返されました | Maxim Group | Buy |
| 2016-10-26 | 開始されました | Aegis Capital | Buy |
| 2016-05-24 | 開始されました | Maxim Group | Buy |
| 2015-10-29 | アップグレード | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | 繰り返されました | MLV & Co | Buy |
| 2015-04-01 | 繰り返されました | MLV & Co | Buy |
| 2015-03-05 | 開始されました | MLV & Co | Buy |
| 2015-02-25 | 開始されました | WBB Securities | Speculative Buy |
| 2015-01-27 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Cytosorbents Corp (CTSO) 最新ニュース
Cytosorbents Corp (CTSO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CytoSorbents Market Sentiment - Benzinga España
Cytosorbents Corp (CTSO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTSO|Cytosorbents Corp|Price:0.360|Chg%:-0.001 - TradingKey
TradingKey - TradingKey
Cytosorbents Corp (CTSO) Cash Flow - TradingKey
CTSO|Cytosorbents Corp|Price:0.360| - TradingKey
Cytosorbents Corp (CTSO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cytosorbents Corp (CTSO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CTSO|Cytosorbents Corp|Price:0.361|Chg%:-0.021 - TradingKey
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights - BioSpace
CytoSorbents (CTSO) to Release Q2 Financial Results on July 30 - GuruFocus
CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CytoSorbents (NASDAQ: CTSO) falls below Nasdaq $35M value test, faces 180-day cure - Stock Titan
CTSO | Cytosorbents Corp. Executive Compensation - Quiver Quantitative
[ARS] Cytosorbents Corp SEC Filing - Stock Titan
CytoSorbents (NASDAQ: CTSO) seeks reverse split to support Nasdaq listing - Stock Titan
CytoSorbents (NASDAQ: CTSO) Targets Major ICU & Cardiac Surgery Markets With Breakthrough Blood Purification Tech, Eyes 2026 Cash Flow Breakeven and FDA Approval 246 - Minichart
CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs - TradingView
CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA meetings, sales and cash flow goals - Stock Titan
Cytosorbents Corp (CTSO) Institutional Confidence - TradingKey
CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026 - Yahoo Finance
Cytosorbents Corp (CTSO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytosorbents Corp (CTSO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cytosorbents Corp (CTSO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cytosorbents (CTSO) Drops 9% as Shares Test Key Support at $0.45PCR Mean Reversion - dars.gov.et
Cytosorbents CFO Peter Mariani buys $44,000 in stock - Investing.com UK
Cytosorbents CFO Peter Mariani buys $44,000 in stock By Investing.com - Investing.com India
Cytosorbents (CTSO) CFO Peter Mariani buys 100,000 shares in open market - Stock Titan
Cytosorbents CEO Phillip Chan buys $104,897 in company stock - Investing.com
CTSO | Cytosorbents Corp. FinancialsIncome Statement - Quiver Quantitative
Cytosorbents (CTSO) CEO boosts stake with 261,469-share open-market buy - Stock Titan
Cytosorbents (CTSO) Q1 2026 Earnings: EPS Miss Overshadows Progress, Yet Stock Gains 3%Pre-Announcement Alert - DonanımHaber
Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near? - simplywall.st
CytoSorbents (NASDAQ: CTSO) asks shareholders to OK 1-for-5–1-for-20 reverse split - Stock Titan
CytoSorbents Corp stock (US23283M1018): Q1 miss keeps focus on growth and cash runway - AD HOC NEWS
CTSO Technical Analysis & Stock Price Forecast - Intellectia AI
CytoSorbents Corp stock (US23283M1018): analyst sentiment and low share price keep focus on Nasdaq-l - AD HOC NEWS
CytoSorbents Corp stock (US23283M1018): Nasdaq price action and valuation metrics in focus - AD HOC NEWS
CTSOCytosorbents Corp Stock Price and Quote - Finviz
Cytosorbents Earnings Call Balances Progress and Pressure - The Globe and Mail
Why Cytosorbents (CTSO) Just Dropped -1.78% — What to Watch 2026-05-20Expert Momentum Signals - Newser
Earnings call transcript: CytoSorbents Q1 2026 misses forecasts, stock falls - Investing.com
Cytosorbents (CTSO) Q1 2026 Disappoints — EPS $-0.08 Below $-0.06 ViewsDividend Growth Analysis - Newser
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytosorbents Earnings Call Balances Progress And Pressure - The Globe and Mail
CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - BioSpace
CytoSorbents Corp (CTSO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth - GuruFocus
Is CytoSorbents (CTSO) a Value Trap Despite 39.9% Undervaluation - GuruFocus
CytoSorbents (CTSO) Reports Q1 Revenue Growth - GuruFocus
Cytosorbents Corp (CTSO) 財務データ
収益
当期純利益
現金流量
EPS
Cytosorbents Corp (CTSO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Chan Phillip P. | Chief Executive Officer |
Jun 12 '26 |
Buy |
0.40 |
251,136 |
100,454 |
1,734,099 |
| Chan Phillip P. | Chief Executive Officer |
Jun 15 '26 |
Buy |
0.43 |
10,333 |
4,443 |
1,744,432 |
1.04%
11.95%
大文字化:
|
ボリューム (24 時間):